Pre- and post-transplant factors associated with body weight parameters after liver transplantation - A systematic review and meta-analysis by Beckmann, Sonja et al.
Factors related to body weight parameters in liver transplantation 
 
 1 
Submission to: Transplantation Reviews 
Type of manuscript: Overview 
Word count: 3943/5000 (body only),5/5 tables/figures, 55/125 references 
 
 
 
Pre- and Post-Transplant Factors Associated with Body Weight Parameters after 
Liver Transplantation – A Systematic Review and Meta-Analysis 
 
 
 
Sonja Beckmann MScNa,b, Gerda Drent PhD, RNc, Todd Ruppar PhD, RNd, Nataša 
Nikolić MScNe, Sabina De Geest PhD, RNa,f 
 
 
a Institute of Nursing Science, Department Public Health, University of Basel, 
Bernoullistrasse 28, CH-4056 Basel, Switzerland, e-mail: sonja.beckmann@unibas.ch 
b Department of Abdomen-Metabolism, University Hospital Zurich, Rämistrasse 100, 
8091 Zurich, Switzerland 
c University of Groningen, University Medical Center Groningen, Department of 
Gastroenterology and Hepatology, Groningen, The Netherlands, e-mail: 
drentgd@gmail.com 
d Rush University College of Nursing, 600 S. Paulina St., Suite 1057A, Chicago, Illinois 
60612 United States of America, e-mail: todd_ruppar@rush.edu 
e Department of Neurosurgery, University Hospital Zurich, Rämistrasse 100, 8091 
Zurich, Switzerland, e-mail: natasa.ivanovic@gmx.ch 
f Department of Public Health and Primary Care, Academic Center for Nursing and 
Midwifery, KU Leuven, Leuven, Belgium, e-mail: sabina.degeest@unibas.ch 
 
 
Corresponding author: Sabina De Geest, Institute of Nursing Science, Department 
Public Health, University of Basel, Switzerland, Bernoullistrasse 28, CH-4056 Basel, 
Tel: +41 (0)61 267 09 51; e-mail: sabina.degeest@unibas.ch 
 
Factors related to body weight parameters in liver transplantation 
 
 2 
Abstract 
Background: Weight gain and obesity can increase liver transplant (LTx) recipients’ disease 
burden. We aimed to summarize and synthesize the evidence on pre- and post-transplant 
factors related to post-LTx BMI, weight gain, and obesity. 
Methods: For this systematic review and meta-analysis we searched Medline (PubMed), 
Cochrane library, CINAHL, PsycINFO, and EMBASE for quantitative studies on 6 classes of 
factors (i.e., genetic, sociodemographic, behavioral, biomedical, psychological, and 
environmental) linked to body weight parameters in adult first-time LTx patients. A 19-item 
instrument was used for quality assessment. Odds ratios (ORs) with 95% confidence 
intervals (CIs) were calculated for relationships investigated in 5 studies. Factors 
investigated in <5 studies were summarized and described. 
Results: Of 16495 articles retrieved, 43 assessed factors in LTx. These examined 82 mainly 
biomedical and sociodemographic factors. However, variation between definitions allowed 
inclusion of only 2 factors (i.e., tacrolimus, cyclosporine) in our meta-analyses of 6 studies 
examining a shared parameter for body weight (median patient sample: 171 (range: 63 - 
455); Europe n = 3; United States n = 3; publication years: 1997–2015). Neither tacrolimus 
(OR, 0.75; 95% CI, 0.47-1.21; p = 0.24) nor cyclosporine (OR, 1.40; 95% CI, 0.89-2.18; p = 
0.14) were related significantly with post-LTx obesity. 
Conclusions: Evidence on modifiable factors related to post-LTx body weight parameters is 
still scarce, as definition variability limits data extraction and pooling for meta-analyses. To 
facilitate future research, studies should apply theoretical frameworks to guide their study 
design, select variables of interest and systematically examine interrelationships among 
selected factors.  
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SD, standard deviation 
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Background 
Obesity, defined as a body mass index (BMI) 30 kg/m2, has become a major health issue in 
the liver transplant (LTx) population. An analysis of the Scientific Registry of Transplant 
Recipients in the United States (US) revealed that, from 2001 to 2011, reflecting a general 
worldwide trend towards rising BMI values [1], the prevalence of obesity in LTx candidates 
rose from 29% to 34.4% [2]. Post-LTx weight gain increases this figure further in the 
recipients. Independent of geographical region or research era, obesity increased from pre-
LTx to 1 year post-LTx in studies from the US (14.5% to 23.8%) [3], the United Kingdom 
(12.6% to 23.7%) [4], and Poland (1.3% to 14.7%) [5]. However, these values must be 
evaluated carefully, as their reported measurements do not necessarily account for pre-LTx 
fluid overload (e.g., edema), which biases measurement of BMI, i.e., body weight in 
kilograms divided by the square of height in meters (kg/m2). As this would falsely inflate the 
prevalence of obesity at LTx, the rise of its post-LTx prevalence may be even more 
pronounced. In fact, a recent Swiss prospective cohort study measuring weight gain between 
6 months and 3 years post-LTx noted a mean weight gain of 4.8 kg, which increased the 
prevalence of obesity in their sample from 5.9% to 18.8% [6]. 
In general, weight gain is the result of complex interactions between biological 
(including genetic), behavioral, social, and environmental factors [7]. Post-LTx weight gain is 
often attributed to immunosuppressive medication–especially prednisone, as its side effects 
include enhanced appetite, a craving for sweets and increased intake of high-fat foods [8, 9]. 
However, not all available evidence supports this relationship [10, 11]. Conflicting results 
have also been reported in view of other biomedical (cyclosporine) [5, 11, 12], 
sociodemographic (age and gender) [3-5, 11], and behavioral factors (current and former 
smoking) [3, 11, 12]. However, a clear understanding of post-LTx body weight factors is 
important as both weight gain and obesity are associated with metabolic syndrome [13, 14]. 
As the LTx population is already exposed to a higher risk for metabolic and cardiovascular 
diseases due to immunosuppressive medications [15-19], the possibility that obesity might 
exacerbate their burden of disease is worrisome.  
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 Examining risk factors for post-LTx body weight parameters offers three main 
advantages: it identifies patients at risk for weight gain and subsequent obesity; it facilitates 
understanding of pathways to weight gain; and it exposes modifiable risk factors. Together, 
these provide a firm basis upon which to develop preventive interventions against weight 
gain and obesity [20, 21]. Therefore, the primary aim of this systematic review and meta-
analysis was to summarize and synthesize the evidence regarding pre- and post-LTx risk 
factors influencing body weight parameters such as BMI, obesity, and weight gain. 
 
Methods 
The methodology of this systematic review and meta-analysis followed the recommendations 
of the Cochrane Handbook for Systematic Reviews of Interventions [22]. Reporting was 
structured according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: PRISMA statement [23]. The review protocol was registered in the international 
prospective register of systematic reviews (PROSPERO, registration number: 
CRD42014009151) and published [24].  
 
Information sources and search strategy 
We searched the following electronic databases without limits: Medline via PubMed, 
Cochrane library, CINAHL, PsycINFO, and EMBASE. To identify relevant additional studies, 
we screened reference lists of studies in included in data extraction. The search string was 
developed according to PICOS criteria (Participants, Interventions/Exposure, Comparisons, 
Outcomes/Topics, Study design). To allow a broad variety of search results, search strings 
were restricted to two concepts: ‘participants’ and ‘exposure’. The first string was developed 
for PubMed (see Table 1) and later translated for the remaining databases in collaboration 
with a librarian. The first search was conducted March 17, 2014 and updated February 3, 
2016. As the project aimed to examine risk factors related to body weight parameters in 
kidney, liver, heart and lung transplant populations, the search strategy included all solid 
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organ groups [24]. However, this article only reports the risk factors affecting the LTx 
population. 
 
Inclusion and exclusion criteria 
Studies were included if they met following criteria: (1) original quantitative or mixed-method 
study design; (2) first-time liver, heart, lung or kidney transplant candidates or recipients 
aged ≥18 years; (3) examination of risk factors or correlates associated with post-LTx body 
weight parameters; (4) study reported in English, German, Dutch or French; and (5) full text 
available. Studies with other than original quantitative or mixed-method study design (e.g., 
case reports, reviews, editorials, letters to the editor, qualitative research), focusing on re-
transplanted or multi-organ transplant recipients, or not examining any relationship between 
body weight parameters and other variables, were excluded. 
 
Study selection  
In accordance with the inclusion and exclusion criteria, title and abstract screening (stage 1) 
then full text reading (stage 2) were performed by three researchers (SB, GD, NN) for the 
first search, and by two researchers for the 2016 search update (SB, GD). In both stages of 
the study selection process, the studies were divided into equal work packages. Each 
researcher independently evaluated the studies of the allocated work package. For feasibility 
reasons, as the first literature search retrieved 13367 hits, we deviated from the Cochrane 
Collaboration recommendation that at least two people should independently select studies 
and then verify all results [22]. For quality monitoring, the study selection process was first 
pilot-tested and evaluated in 50 studies for stage 1 and in 6 studies for stage 2. Researchers 
then cross-checked a random sample of 10% of one another’s in- and exclusion decisions. 
Disagreements were resolved by discussions with a third researcher (SDG) until consensus 
was reached. 
 
Data extraction and management 
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Data extraction of the studies included in the meta-analysis was performed independently by 
two researchers (SB, GD). In cases where an article provided either insufficient data for 
extraction or conflicting information, the author was contacted for additional information at 
most twice via e-mail or research network platforms. The following general variables were 
extracted: general information (author, year, journal, continent, country, language, setting, 
database, study design, time of transplant), population (donor, etiology of liver disease, 
model of end-stage liver disease score, sample size, age, gender, race, follow-up time, 
correction for ascites, definition of BMI categories), details on statistical analysis, and body 
weight parameters (BMI and BMI category at LTx and post-LTx, as well as post-LTx weight 
gain). For the purposes of this study, we defined weight categories with the most commonly 
used BMI classification–that proposed by the World Health Organization (WHO)–as an 
accurate outcome measure: underweight: <18.5 kg/m2; normal weight: 18.5-24.9 kg/m2; 
overweight: 25-29.9 kg/m2; and obesity ≥ 30 kg/m2 [25].  
 As weight gain and obesity result from a complex interplay of factors [7], we used a 
previous extensive overview [26] to develop a guiding framework, and categorized pre- and 
post-LTx factors as follows: genetic (e.g., single genes, family history of overweight), 
sociodemographic (e.g., age, gender, education, marital status, income level, working 
status), behavioral (e.g., energy intake, energy expenditure, physical activity, smoking), 
biomedical (e.g., BMI category, end-stage organ disease, hemodialysis, medication), 
psychological (e.g., stress, quality of life), and environmental (e.g., public transportation, 
availability of exercise areas). 
 
Quality assessment 
Study quality of the meta-analyzed studies was assessed independently by two researchers 
(SB, GD) via a 19-item instrument (see supplemental digital content, table 1), which was 
adapted from two other tools: the 27-item Downs and Black checklist [27] and a quality 
assessment instrument used for Duerinckx et al.’s 2016 systematic review [28]. The results 
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of the quality assessment were visualized via the Cochrane Risk of Bias summary figure 
provided by Cochrane Review Manager 5.3) [29].  
 
Data analysis  
Study characteristics were presented using descriptive statistics. Where mean values for age 
or BMI were only provided for subgroups, a weighted mean was calculated for the total 
sample. Only risk factors assessed in 5 studies were included in the meta-analysis. Effect 
sizes were calculated to analyze the strengths and directions of relationships, and were 
expressed as odds ratios (OR) for associations between risk factors and post-LTx body 
weight parameters. All effect sizes were reported with the corresponding 95% confidence 
intervals (CIs). Because we expected sample heterogeneity among the primary studies, 
estimated effects were pooled using a random-effects model. The included studies’ 
heterogeneity was assessed using both the Cochrane Q test (with a p value <0.1 indicating 
significant heterogeneity) and I2 statistics, with values of 25%, 50%, and 75% respectively 
indicating moderate low, moderate, and high heterogeneity [30]. Subgroup analyses using 
year of publication and geographical location as moderators were conducted with meta-
analytic versions of regression (for continuous moderators) and ANOVA (for dichotomous 
moderators). Risk factors assessed in <5 studies were grouped within their categories and 
classed as significant or nonsignificant based on their relationship with the body weight 
parameter. The results were summarized graphically. All analyses were conducted using 
Comprehensive Meta-Analysis software (Biostat, Inc., Englewood, NJ, USA). 
 
Results 
Study selection and assignment to the categories 
The study selection process is shown in Figure 1. Of 16495 initial references, 43 studies in 
LTx met the inclusion criteria. These assessed 82 distinct pre-and post-LTx factors in relation 
to any of the 3 body weight parameters (i.e., post-LTx BMI, obesity and weight gain). Overall, 
factor definitions varied hugely, which limited pooling to groups of at least 5 studies 
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examining the same factor in relation to the same body weight parameter of interest. Two 
factors (i.e., tacrolimus and cyclosporine) were examined in 6 studies vis à vis post-LTx 
obesity, making them eligible for data extraction and meta-analysis [13, 31-35].   
Summary of factors examined in relation to post-LTx body weight parameters 
Figure 2 shows an overview of factors studied in fewer than 5 studies in relation to post-LTx 
BMI, obesity and weight gain. The majority of factors examined were categorized as 
biomedical and sociodemographic. Within the pre-LTx biomedical factors, diabetes mellitus 
and BMI were studied 5 times in relation to either BMI, obesity or weight gain and 
represented the highest number of significant results relative to the total number of studies 
(respectively 3/5 and 5/5). Among the post-LTx biomedical factors of interest, 4 types of 
immunosuppressive medication were frequently examined in relation to the 3 body weight 
parameters, but generally yielded low proportions of significant results: steroids (2/12), 
cyclosporine (2/8), tacrolimus (0/7), and sirolimus (2/3). In the group of pre-LTx 
sociodemographic factors, gender and age were studied most frequently, both with mixed 
results regarding their impact (2/7 and 2/5). Very few studies examined behavioral, genetic or 
psychological risk factors; none examined environmental factors. 
 
Characteristics of the studies included in meta-analysis 
The characteristics of the 6 studies examining tacrolimus and cyclosporine as possible 
factors of post-LTx obesity are summarized in Table 3. All 6 were single-center studies from 
either Europe (n = 3, 50%) or the US (n = 3, 50%), and were published between 1997 and 
2015. The median sample size was 171 patients (range, 63 – 455). Distributions of patients 
within BMI categories were not provided in all of the studies, nor were BMI category 
definitions used consistently. The final set of studies did not include companion papers. 
 
Risk factors for post-LTx obesity  
The 6 included studies, involving a total of 1177 participants, showed no association between 
tacrolimus and post-LTx obesity (OR, 0.75; 95% CI, 0.47-1.21; p = 0.24) (Figure 3). There 
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was low but non-significant heterogeneity among the studies (Q, 7.12; p = 0.21; I2 = 29.75%). 
A subgroup analysis based on year of study publication did not show a significant result (β = 
0.05; p = 0.18); nor did a subgroup analysis based on where each study was conducted 
(Europe, including Turkey: mean OR, 0.56; 95% CI, 0.26-1.28; US: mean OR, 0.95; 95% CI, 
0.506-1.791; p = 0.33). 
Further, no association was shown between cyclosporine use and post-LTx obesity 
(OR, 1.40; 95% CI, 0.89-2.18; p = 0.14). Heterogeneity among the studies was non-
significant (Q = 4.67; p = 0.46; I2 = 0.00%). As with the tacrolimus analysis, cyclosporine 
yielded no significant difference in study effect sizes based on year of publication (β = -0.03, 
p = 0.34); and no difference was shown due to study location (Europe, including Turkey: 
mean OR, 1.64 95% CI, 0.871-3.088); US: mean OR, 1.15 05% CI, 0.59-2.25; p = 0.45). 
 
Quality assessment 
The results of the quality assessment are shown in the supplementary material Figure 4. All 
studies had retrospective study designs (n = 6, 100%); four (66.6%) had sample sizes large 
enough to test individual predictor variables. None used a theoretical framework to guide the 
research process or the selection of study variables; and none reported studying 
representative samples (selected via probability sampling). Three studies (50%) clearly 
described the patient characteristics needed to apply our systematic review’s inclusion and 
exclusion criteria. All 6 adequately described the results and the variables of interest, i.e., the 
factors analyzed in relation to body weight parameters. Although 2 (33.3%) took confounders 
into account, none adjusted adequately for them in the analysis. Based on the methods 
described in the articles, 3 studies (50%) met the criteria for reproducibility.  
 
Discussion 
This systematic literature review summarized pre- and post-LTx factors relating to post-LTx 
BMI, obesity, and weight gain. In all, 82 factors were identified, mainly from the biomedical 
and sociodemographic categories. Behavioral, genetic or psychological factors were less 
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frequently studied, while environmental factors were not examined in relation to any body 
weight parameter. As only tacrolimus and cyclosporine were addressed in more than 5 
studies, they were the only factors eligible for meta-analysis. Neither tacrolimus nor 
cyclosporine was significantly associated with post-LTx obesity. 
 
Examination of factors associated with body weight parameters  
All factors were assigned to our predefined categories. As expected, the majority were 
biomedical or sociodemographic. Most are easily obtainable, as they are among the more 
common sample characteristics in single-center and database-related studies. In spite of a 
large initial search return, however, not enough articles were available to perform more meta-
analyses, as the researchers’ factor definitions varied too greatly. E.g., steroid use was 
defined as use of cortisone (yes/no), cumulative steroid dose, length of steroid use, or use of 
steroids in combination with other immunosuppressive drugs. This level of heterogeneity 
among definitions precluded meta-analyses to test for relationships between 
immunosuppressive drugs and weight-gain parameters, which still warrant further 
investigation [9].  
 Following LTx, metabolic comorbidities such as diabetes, hypertension or 
dyslipidemia commonly occur as side-effects of immunosuppressive medication [17]. 
Although obesity is also classed as a metabolic disorder, few studies have examined 
possible relationships with it. Three out of 5 studies focusing on diabetes found that pre-LTx 
diabetes significantly related to post-LTx obesity and weight gain. Taking another 
perspective, in a recent systematic review, Li et al. examined risk factors for new-onset 
diabetes mellitus after LTx by meta-analyzing 7 studies with information on pre-LTx BMI [36]. 
The results suggest relationships between diabetes and body weight parameters, 
independent of when those parameters were measured; however, testing these relationships 
will require further investigation.  
 Nevertheless, body weight influencing parameters include far more than biomedical 
or sociodemographic factors. As weight gain and subsequent obesity are driven by multiple 
Factors related to body weight parameters in liver transplantation 
 
 12 
interrelated factors, a broader range of variables require consideration [26]. Evidence in the 
general population stresses the importance of socioeconomic (e.g., female gender with low 
income) [37, 38], psychological (e.g., depression) [39], and genetic factors (e.g., BMI- and 
obesity-related genes such as FTO, MC4R, or BDNF) [40]. Yet, the examination of those 
specific factors in large samples is often limited because they are not included per se in 
standardized database or registry data collection.   
 Behavioral factors, e.g., healthy eating and physical activity, represent another 
important component in relation to body weight parameters. Still, while their value to prevent 
weight gain has been shown in the general population [41, 42], evidence in the LTx 
population is lacking. Two quantitative studies asked LTx recipients their opinions regarding 
the causes of weight gain after LTx [16, 43]. Interestingly, increased food intake, constant 
hunger, and decreased daily physical activity were among the most common responses. 
Although these findings suggest that patients perceive behavioral factors as relevant to 
weight gain, this relationship needs further examination in both qualitative and quantitative 
research. Examining barriers to physical activity after transplantation, a small study in kidney 
recipients found that, alongside fear of injuring the new kidney, health problems such as pain 
were limiting post-LTx activity levels, as well as time constraints after they returned to work 
[44]. These findings not only provide preliminary insights regarding post-kidney transplant 
non-performance of physical activity, but also emphasize behavior’s relationships with other 
factors (e.g., psychological [i.e., fear, anxiety], biomedical [i.e., pain], and sociodemographic 
[i.e., return to work]). Given the complexity of factors related to body weight parameters, 
future research should incorporate theoretical frameworks guiding the choice of study design 
and selection of variables of interest. 
 Overall, the alarming low number of studies examining risk factors and body weight 
parameters in the LTx population indicates an urgent need for further investigation. Yet, 
methodological issues may be a barrier. Various genetic, sociodemographic, behavioral, 
biomedical, psychological, and environmental factors (e.g., epigenetic characteristics, 
monthly income, physical activity, immunosuppressive drugs, moving to another area) can 
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change over the course of Tx. An adequately-sized prospective study cohort that can supply 
repeated measurements, thereby allowing multivariate analyses and the examination of 
interrelationships, would be optimal for this type of research. 
 
Examination of various body weight parameters 
Despite the broad choice of body weight parameters available for study, the majority of study 
authors chose to examine post-LTx obesity (BMI 30 kg/m2). However, none differentiated 
between the WHO’s three obesity classes (class I: BMI 30-34.9 kg/m2; class II: BMI 35-39.9 
kg/m2; class III: 40 kg/m2) [25]. As BMI values 35 kg/m2 have been associated with lower 
patient survival [45], higher post-LTx morbidity and increased healthcare utilization [45-47], 
risk factors associated with obesity classes II and III warrant far more attention. 
 The small number of studies examining post-LTx weight gain–recognized as a health 
issue in LTx since the early 1990s [43] –was also somewhat surprising. Modifiable weight 
gain risk factors could be targeted by preventive interventions, which are widely accepted as 
the key strategy against weight gain and subsequent obesity [48-50]. The reason for this 
approach is the so-called yo-yo effect. In times of lower energy intake, e.g., during a diet, 
compensatory physiological mechanisms lead to reduced energy requirements. Afterwards, 
when energy intake increases to a normal level, to have a reserve available for future 
shortages, the body takes up more energy than actually needed, resulting in weight re-gain 
[51]. Based on the difficulty involved in overcoming these compensatory mechanisms, 
preventing weight gain should logically be easier than achieving and maintaining a target 
weight after weight loss [52]. Therefore, we propose the identification of risk factors 
associated with post-LTx weight gain as an important area for future research.  
 
Risk factors for post-LTx obesity  
The use of neither tacrolimus nor cyclosporine–both calcineurin inhibitors–was associated 
with post-LTx obesity. Following LTx, tacrolimus has become the immunosuppressive 
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treatment of choice, as it is associated with improved patient and graft survival and reduced 
rejection [53]. Unfortunately, while functioning well as the major pathway of 
immunosuppression, calcineurin inhibition has also been associated with the development of 
metabolic comorbidities such as diabetes mellitus, hypertension, and hyperlipidemia [54]. 
However, our meta-analysis showed no association between either tacrolimus or 
cyclosporine and obesity as a metabolic disorder. Moreover, the literature search retrieved 8 
studies which examined tacrolimus or cyclosporine with weight gain after LTx, however, none 
of those found a significant association.  
 Although heterogeneity was not statistically significant across our sample, the small 
number of studies included in the analysis (n = 6) might have contributed to an inadequate 
statistical power to detect differences across studies. Subgroup analyses considering year of 
study publication and geographical location found no differences.  
 However, several inter-study methodological and clinical disparities may also have 
impacted our analyses. First, from a methodological perspective, obesity alone might not be 
accurate enough as an outcome measure. We did not distinguish in our review between 
obesity per se (which might have been present pre-LTx) and new-onset obesity that 
developed post-LTx. Of the studies relevant to our meta-analyses, only Akarsu et al. 
provided more detailed information about this differentiation, as they examined the factors 
related to obesity’s development [31]. Second, the cutoff values defining obesity differed 
across the 6 studies–one of which provided no BMI cutoff [35]. Third, 3 studies were cross-
sectional, examining the relationship between immunosuppressive drugs and post-LTx 
obesity only at one specific time point, i.e., either 1 [13, 33] or 3 years [35]. The other 3 
assessed post-LTx obesity longitudinally between 1 and 168 months, weakening a precise 
definition of the outcome measured. Finally, as immunosuppressive medications are core 
treatment elements, preventing graft rejection after transplant, studies examining them often 
lack adequate control groups. 
  From a clinical perspective, the amount of immunosuppressive medication applied 
likely varied across the 6 studies and over time. Dosing usually decreases in the post-LTx 
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course to minimize long-term medication-related side effects and comorbidities [55]. Also, in 
case of medication intolerance or other clinical, laboratory, or histological responses, a 
medication regimen might change radically [17]. Finally, based on a growing body of 
research and clinical experience, since the first uses of cyclosporine and tacrolimus–
respectively in the late 1970s and late 1980s–, their application (i.e., amount of medication 
needed, combination of drugs) has improved continuously [55]. Considering that the 6 
studies included in our meta-analysis studied LTx over more than 2 decades (1986 – 2010), 
this long-term development process implies heterogeneity in the prescription of both 
immunosuppressive agents. Neither of these clinical issues (e.g., possible changes of 
immunosuppressive regimen, dosing) was described explicitly in any of the 6 included 
studies.  
 
Limitations 
In addition to the shortcomings already mentioned in the discussion, this study has additional 
limitations. First, as noted, we could only include a small number of observational studies. 
Results should therefore be interpreted with caution. Second, the definitions and reporting 
methods varied across all 43 articles examining risk factors. This hindered the extraction of 
variables needed for the final meta-analysis. Additionally, although we applied no time limit 
for the search, data extraction from studies performed more than 10 years ago was 
sometimes limited due to information missing from reports or articles, as authors did not 
typically archive their data or respond to requests for additional information. Third, the 
inclusion criteria that all participants be aged ≥18 led to the exclusion of a number of papers, 
especially from the earlier transplantation era, when adults were often defined as aged ≥16 
years. Fourth, due to a lack of reported data, we were not able to include information on body 
composition or waist circumference, both of which are important and informative body weight 
parameters. Finally, due to the small number of eligible studies, we were unable to perform 
more comprehensive subgroup analyses, examining moderators such as type of transplant, 
study setting, ethnicity, age, gender, adjustment for ascites or co-morbidities. 
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Conclusion 
We identified 82 distinct pre- and post-LTx factors examined in relation to BMI, obesity and 
weight gain after LTx. The factors studied were mainly categorized as biomedical and 
sociodemographic. Unfortunately, strong variations in factor definitions limited the pooling to 
groups of at least 5 studies for meta-analysis. Only two factors were eligible for meta-
analysis: tacrolimus and cyclosporine. Neither was significantly associated with post-LTx 
obesity. Subgroup analyses focusing on year of publication and geographical region yielded 
no significant results. Further research is necessary to identify modifiable factors associated 
with post-LTx weight gain and obesity, to facilitate development of preventive interventions. 
Future studies should apply theoretical frameworks to select variables of interest and 
systematically examine interrelationships among different factors.  
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Table 1. Detailed PubMed search string  
 
(("Body Mass Index"[Mesh] OR "obesity"[Mesh] OR "overweight"[MeSH Terms] OR 
"Weight Gain"[Mesh] OR "Body Weight Changes"[Mesh:noexp] OR "Body 
Weight"[Mesh:noexp]) OR ("BMI"[Text Word] OR "Body Mass Index"[Text Word] OR 
"obesity"[Text Word] OR "overweight"[Text Word] OR "weight gain"[text word] OR "body 
weight change*"[Text Word] OR "body weight"[Text Word] OR "weight"[Text Word] OR 
"Ideal Body Weight"[Mesh] OR "weight management"[Text Word] OR "body size"[Text 
Word]) AND ("organ transplant*"[Text Word] OR "transplant*"[Text Word] OR "heart 
transplant*"[Text Word] OR "liver transplant*"[Text Word] OR "lung transplant*"[Text Word] 
OR "kidney transplant*"[Text Word]) OR ("Kidney Transplantation"[Mesh] OR "Lung 
Transplantation"[Mesh] OR "Heart Transplantation"[Mesh] OR "Liver 
Transplantation"[Mesh] OR "Organ Transplantation"[Mesh:noexp] OR 
"Transplantation"[Mesh:noexp])) 
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Table 2. Characteristics of studies included in meta-analysis 
 
Study 
Year 
Country Design 
Setting 
 
Time of 
LTx 
 
Follow up Partici-
pants, n 
 
Male 
gender, 
(%) 
 
Age at LTx,  
mean  SD, 
median 
(range) 
BMI at 
LTx,  
mean  
SD  
 
Patients in different BMI 
categories§ at LTx,  
n (%) 
Akarsu et al. 
2013 
Turkey Retrospective 
cohort study, 
single center 
01.2001 -
01.2010 
5 years 226 66.8 46.19  10.2 25.7  4.2 Underweight°: 13 (5.8) 
Normal weight#: 96 (42.5) 
Overweight: 84 (37.1) 
Obese: 33 (14.6) 
Bianchi et al. 
2006 
Italy Retrospective 
cohort study, 
single center 
06.2001 -
09.2003 
median 40 mo  
(range 6-164) 
230 66.1 53 (18-66) 26  4 Overweight: 120 (52) 
Obese: 25 (11) 
Canzanello et 
al.  
1997 
U.S. Retrospective 
cohort study, 
single center 
NA 1 year 63 
 
39.7 47.9* 25.98*  Obese”: 15 (23.8) 
Fernandez-
Miranda et al. 
2002 
Spain Case control 
study,  
single center 
11.1986 - 
03.1995 
median 102 mo  
(range 60-168) 
116 64.6 51.2  12.6 26.2  4.8 Obese: 26 (22.4) 
Fussner et al.  
2015 
U.S. Retrospective 
cohort study, 
single center 
12.1998 -
12.2004 
8-12 years 455 64 51.8  10.3 26  8 NA 
Rabkin et al.  
2002 
U.S. Case control 
study,  
single center 
1994 -
1998 
3 years 87 62 46.7* NA Obesity defined as 
indicated diagnosis, 
sample size NA 
 
LTx, liver transplantation; SD, standard deviation; BMI, body mass index; NA, not available; mo, months 
* Calculated weighted mean 
§ categories defined according to WHO, otherwise indicated: 
° BMI: <20 kg/m2, # BMI: 20-24.9 kg/m2, " ≥ 27.8 kg/m2 in men, ≥ 27.3 kg/m2 in women 
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Figure 1. Flowchart according to PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) statement 
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Duplicate  n = 9  
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Content  n = 492 
 
Studies included in qualitative 
synthesis (n = 1018) 
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Liver  n= 224 
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Lung  n= 52 
(7 studies examined >1 organ group) 
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Studies assessing risk factors  n = 43 
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Figure 2. Pre- and post-LTx risk factors of post-LTx obesity, weight gain and BMI assessed by 1 to 4 studies 
 
 
NASH, nonalcoholic steatohepatitis; HCV, hepatitis C Virus; BMI, body mass index; UNOS, United Network for Organ Sharing; Tx, transplantation; HCC, hepatocellular carcinoma;   
Pred, prednisone; Aaz, Azathioprine, CsA, cyclosporine; Tac, Tacrolimus; CVD, cardiovascular disease 
Biomedical Sociodemographic Biomedical Sociodemographic Biomedical Sociodemographic
NASH Gender Cryptogenic cirrhosis Gender BMI at Tx Gender
Alcohol cirrhosis Age Alcohol cirrosis Age Etiology Age
Etiology of liver disease Marital status Autoimmune hepatitis Race PBMNC complex I activity
Alcoholic cirrhosis & HCV Education Cirrhosis with HCC Education Cyclosporine Behavioral
Cholestatic liver disease Income Etiology of liver disease Income Tacrolimus 1 or 2/daily Physical activity 
Acute hepatic failure Hepatitis C Marital status Corticosteriods Health practices
Donor BMI Behavioral Hypertension Employment status Length of steroid use Health behaviors
Fat in donor liver Smoking Hyperglycemia Education Sirolimus Proper dietary habits
Muscle waisting Physical activity Diabetes mellitus Azathioprine Preventive behaviours
Intraoperative ascites BMI at Tx Behavioral Diabestes Mellitus Fat intake (g/kg) 
Dialysis Genetic Donor sex Smoking Steatosis
Diabetes mellitus PNPLA-3 GG genotype Donoe age Former smoking Hepatitis C  Genetic
Karnofsky score IL28B genotype Donor BMI Length of hospital stay PNPLA-3 GG genotype
Child-Pugh status Cyclosporine Genetic Rejection episodes
UNOS status Psychological Tacrolimus PNPLA-3 GG genotype Organ type Psychological
BMI at Tx Sleeping time per night Azathioprine Fam. history diabetes Fatigue severity Sleep quality
Weight loss during disease Distress by appetite Corticosteriods Fam. history CVD Triglycerides Quality of Life
BMI before liver disease Quality of Life Length of steroid use Fam. history hypertension Cholesterol Positive mental attitude
Corticosteriods Cumulative steroid dose Fam. history overweight Serum osteocalcin
Length of steroid use Pred, Aza, CsA Number of studies 1 2 3 4 Number of studies 1 2 3 4
Cumulative steroid dose Pred, Aza, Tac Psychological
Sirolimus Diabestes Mellitus Sleeping time per night
Azathioprine Triglycerides 
Diabestes Mellitus Cholesterol 
Length of hospital stay Number of studies 1 2 3 4 Number of studies 1 2 3 4
Rejection episodes
Acute rejection 1st year
Re-Tx
Health kept from work
Trouble walking / stairs
Weight gain Significant (p < 0.05)
BMI Not significant
Waist circumference 
Body composition
Number of studies 1 2 3 4 Number of studies 1 2 3 4
Obesity after LTx Weight gain after LTx BMI after LTx
Pre-Tx factors straight font
Post-Tx factors italics
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Figure 3. Forest plot of studies analyzing tacrolimus and cyclosporine in relation to post-LTx 
obesity in ≥5 studies  
 
Tacrolimus 
 
Cyclosporine 
 
 
 
CI, confidence interval 
 
 
Author (Year) ComparisonOutcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Akarsu et al. 2013 Tacrolimus Obesity 1.036 0.523 2.053 0.919
Bianchi et al. 2006 Tacrolimus Obesity 0.275 0.079 0.950 0.041
Canzanello et al. 1997 Tacrolimus Obesity 0.480 0.163 1.418 0.184
Fernandez-Miranda et al. 2002 Tacrolimus Obesity 0.453 0.156 1.318 0.146
Fussner et al. 2015 Tacrolimus Obesity 1.180 0.499 2.792 0.706
Rabkin et al. 2002 Tacrolimus Obesity 1.474 0.446 4.879 0.525
0.751 0.465 1.213 0.242
0.1 0.2 0.5 1 2 5 10
Less Obesity More Obesity
Meta Analysis
Author (Year) Comparison Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Akarsu et al. 2013 Cyclosporine Obesity 1.136 0.433 2.982 0.795
Bianchi et al. 2006 Cyclosporine Obesity 3.640 1.052 12.588 0.041
Canzanello et al. 1997 Cyclosporine Obesity 2.082 0.705 6.143 0.184
Fernandez-Miranda et al. 2002 Cyclosporine Obesity 1.426 0.541 3.760 0.473
Fussner et al. 2015 Cyclosporine Obesity 0.750 0.218 2.578 0.648
Rabkin et al. 2002 Cyclosporine Obesity 0.841 0.257 2.749 0.775
1.395 0.892 2.181 0.144
0.1 0.2 0.5 1 2 5 10
Less Obesity More Obesity
Meta Analysis
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Supplementary material Table 1: Quality assessment instrument  
 
No Question Definition Rating 
Aim 
 
1 
Is the hypothesis / aim / 
objective of the study clearly 
described? 
  Yes  
 No  
 Unable to determine 
 
2 
Does the study have a 
prospective design? 
 
Yes:  
 Prospective data collection 
 Yes  
 No 
 Unable to determine 
Participants 
 
3 
Are the characteristics of the 
patients included in the study 
clearly described? 
 
Yes: 
 Cohort studies and trials: inclusion 
and/or exclusion criteria given  
 Case-control studies: a case-definition 
and source for controls is given 
No:  
 No information about precise age, 
multi-organ or re-transplant 
 Yes  
 No   
 Partially 
 
4 
Were the subjects asked / 
chosen to participate in the 
study representative of the entire 
population from which they were 
recruited? 
 
Meaning: Identify the source 
population for patients and 
describe how the patients were 
selected 
 
 
Yes:  
 Sample comprises the entire source 
population 
 Unselected sample of consecutive 
patients 
 Random sample 
 Patients from more than one center or 
study setting included 
No: 
 Single center setting 
Unable to determine: 
 Study does not report the proportion of 
the source population from which the 
patients are derived 
 Yes  
 No 
 Unable to determine  
 
5 
Were the patients in different 
intervention groups (trials and 
cohort studies) or were the 
cases and controls (case-control 
studies) recruited from the same 
population? 
 
Yes: 
 Patients for all comparison groups 
were selected from the same hospital / 
population / cohort 
Unable to determine:  
 In cohort and case-control studies: no 
information concerning the source of 
patients included  
 Yes  
 No 
 Unable to determine  
 
6 
Were study subjects in different 
intervention groups (trials and 
cohort studies) or were the 
cases and controls (case-control 
studies) recruited over the same 
period of time? 
 
Yes:  
 All patients recruited over the same 
period of time 
Unable to determine: 
 Time period over which patients were 
recruited for the study is not specified 
 Yes  
 No 
 Unable to determine  
 
7 
Were losses of patients to 
follow-up taken into account? 
 
Yes: 
 If the proportion lost to follow-up was 
too small to affect the main findings 
Unable to determine: 
 Numbers of patients lost to follow-up 
are not reported  
 Yes  
 No 
 Unable to determine  
Outcomes  
 
8 
Are the main outcomes to be 
measured clearly described in 
the introduction or methods 
section? 
 
No: 
 If main outcomes are first mentioned in 
the results 
 No cutoffs for BMI categories given 
 Yes  
 No   
 Partially 
 
9 
Were the main outcome 
measures used accurate (valid 
and reliable)? 
 
Yes:  
 Outcome measures clearly described 
(psychometrics, values) 
 Studies referring to other work or 
demonstrate the outcome measures 
are accurate (reference given) 
No:  
 not WHO definition for BMI categories 
 Yes  
 No 
 Unable to determine 
 
10 
Are the variables of interest 
clearly described? 
 
Yes:  
Clear description of content such as 
 Changes of weight, BMI 
 Risk factors 
 Yes  
 No   
 Partially  
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 Consequences / outcomes 
 
Results 
 
11 
Are the main findings of the 
study clearly described? 
 
Yes:  
 Simple outcome data reported for all 
major findings  
This question does not cover statistical 
tests. 
 Yes  
 No   
 Partially 
 
12 
Have actual probability values 
been reported for the main 
outcomes except where the 
probability value is < 0.001? 
Yes: 
 0.035 rather than <0.05 
 Yes  
 No   
 Partially 
 
13 
Does the study provide 
estimates of the random 
variability in the data for the 
main outcomes? 
 
Yes:  
 According to distribution of data, 
results include: 
o Non-normal: IQR 
o Normal: SE, SD or CI 
 If distribution of data is not described, it 
must be assumed that the estimates 
were appropriate  
 Yes  
 No   
 Partially 
 
14 
Are principal confounders 
influencing the outcome clearly 
described? 
Yes:  
 List of principal confounders is 
provided 
 Yes  
 No   
 Partially 
Analysis 
 
15 
In trials and cohort studies, do 
the analyses adjust for different 
lengths of follow-up of patients, 
or in case-control studies, is the 
time period between the 
intervention and outcome the 
same for cases and controls? 
 
Yes: 
 Follow-up was the same for all study 
patients  
 Different lengths of follow-up were 
adjusted for (e.g. survival analysis) 
No:  
 Differences in follow-up are ignored 
 Yes  
 No 
 Unable to determine  
 
16 
Were the statistical tests used to 
assess the main outcomes 
appropriate according to the 
data and the aims? 
 
Yes: 
 Analysis clearly described 
 Little statistical analysis but no 
evidence of bias 
 Risk factors: Multivariate analysis 
 Small sample size: nonparametric 
methods 
 If distribution of the data is not 
described it must be assumed that the 
estimates used were appropriate  
 Yes  
 No   
 Partially 
 
17 
Was there adequate adjustment 
for confounding in the analyses 
from which the main findings 
were drawn? 
 
Randomized studies: 
No: 
 Main conclusions of the study were 
based on analyses of treatment rather 
than intention to treat 
 Distribution of known confounders in 
the different treatment groups was not 
described or not taken into account in 
the analyses 
Non-randomized studies: 
No: 
 The effect of the main confounders 
was not investigated  
 Confounding was demonstrated but no 
adjustment was made in the final 
analyses  
 Yes  
 No 
 Unable to determine  
 
18 
Was the sample size 
appropriate? 
Yes: 
 A priori sample size justification 
 At least 104+x if testing individual 
predictors variables  
 At least 50+8x subjects  
x is the number of independent/ 
predictors variables for testing a 
multiple correlation  
 Yes  
 No 
 Unable to determine  
 
19 
Reproducibility of the study on 
the basis of the description of 
methods and outcomes 
 
Yes:  
 Enough details described that the 
study could be repeated accurately 
 If yes in question: 18, 16, 10, 9, 8, 3 
 Yes  
 No   
 Partially 
 
BMI, Body Mass Index; RCT, randomized controlled trial; WHO, World Health Organization; IQR, 
interquartile range; SE, standard error; SD, standard deviation; CI, confidence interval 
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Instrument adapted from the 27-item checklist by Downs SH, Black N. The feasibility of creating a checklist 
for the assessment of the methodological quality both of randomized and non-randomized studies of 
health care interventions. J Epidemiol Community Health. 1998;52(6):377-384. 
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Supplementary material Figure 4. Quality assessment of the 6 studies included in the 
meta-analysis 
 
 
 
 
Reproducibility of a study was rated with ‘yes’ when all items with an asterisk* were 
rated ‘yes’ in this study. 
 
 
 
